| Document Date: 2014-10-27 08:46:29
Open Document File Size: 46,61 KBShare Result on Facebook
City Co-penhagen / COPENHAGEN / / Company Genentech Inc. / Symphogen A/S / / Country Denmark / / Currency USD / / / Event Business Partnership / / IndustryTerm treatment of serious human diseases / biopharmaceutical / manufactur-ing technologies / ex-pression technologies / manufacturing capabili-ties / recombinant antibody technologies / consistent and reproducible manufacturing / manufacturing / / MedicalCondition cancer / antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN / several disease / undisclosed infectious disease / serious infections / serious human diseases / novel infectious disease / diseases / infectious diseases / infectious agent / / Person Kirsten Drejer / Kari Watson / John Haurum / Thomas Feldthus / / / Position CEO / leader / CFO / General / / Technology Sympress™ technology / biopharmaceuticals / manufactur-ing technologies / Symplex™ technology / recombinant antibody technologies / antibodies / ex-pression technologies / / URL www.symphogen.com / /
SocialTag |
Symphogen Enters into strategic collaboration with Genentech for antibody therapeutics SYMPHOGEN ENTERS INTO STRATEGIC COLLABORATION WITH GENENTECH FOR ANTIBODY THERAPEUTICS IN INFECTIOUS DISEASE COPENHAGEN, Denmark –